
    
      The primary objective of this trial is to determine whether the 24-week L-T4 replacement
      therapy, as an adjunct to standard treatment, would improve exercise capability in chronic
      systolic heart failure patients with subclinical hypothyroidism compared to the standard
      treatment.
    
  